Development of a multidose formulation for a humanized monoclonal antibody using experimental design techniques
- 532 Downloads
The purpose of this study was to identify optimal preservatives for a multidose formulation of a humanized monoclonal antibody using experimental design techniques. The effect of antimicrobial parenteral preservatives (benzyl alcohol, chlorobutanol, methyl paraben, propylparaben, phenol, and m-cresol) on protein stability was assessed using size-exclusion chromatography, differential scanning calorimetry, right-angle light scattering, UV spectroscopy, and potency testing using a cell-based fluorescence-activated cell sorting method. A quick, cost-effective preservative screening test was designed. Combinations of preservatives were examined using an I-optimal experimental design. The protein was most stable in the presence of methylparaben and propylparaben, and was compatible with benzyl alcohol and chlorobutanol at low concentrations. Phenol and m-cresol were not compatible with the protein. The I-optimal experimental design indicated that as an individual preservative, benzyl alcohol was promising. The model also indicated several effective combinations of preservatives that satisfied the antimicrobial efficacy and physical stability constraints. The preservative screening test and the experimental design approach were effective in identifying optimal concentrations of antimicrobial preservatives for a multidose protein formulation; (1) benzyl alcohol, and (2) the combination of methylparaben and chlorobutanol were screened as potential candidates to satisfy the regulatory requirements of various preservative efficacy tests.
Keywordsmultidose formulation preservative experimental design monoclonal antibody protein
- 1.McGoff P, Scher DS. Solution formulation of proteins/peptides. In: McNally EJ, ed. Protein Formulation and Delivery. New York, NY: Marcel Dekker, 2000:139–158.Google Scholar
- 2.Akers MJ, Defelippis MR. Peptides and proteins as parenteral solutions. In: Frokjaer S, Hovgaard L, eds. Pharmaceutical Formulation Development of Peptides and Proteins. Philadelphia, PA: Taylor and Francis; 2000:145–177.Google Scholar
- 3.Bontempo JA. Formulation development. In: Bontempo JA, ed. Development of Biopharmaceutical Parenteral Dosage Forms. New York, NY: Marcel Dekker; 1997:109–142.Google Scholar
- 6.Akers MJ. Considerations in selecting antimicrobial preservatives for parenteral product development. Pharm Technol. 1984;8(5):36–44.Google Scholar